Cynvenio Releases ClearID® Lung Cancer: a Highly-Targeted Genomic Blood Test for Lung and Thoracic Cancer Patients

May 16, 2017 – Cynvenio announces the release of its ClearID Lung Cancer blood test. Leveraging a highly-sensitive next-generation sequencing panel of 11 genes known to be altered in lung cancer, this new test is designed to quickly and accurately identify tumor-related genetic mutations that can be treated with targeted therapies.

Cynvenio Clinical Trial Data Supports Benefits of Multi-Template Liquid Biopsy Sequencing for Cancer Mutational Profiling

April 5, 2016 — Molecular diagnostic approaches to cancer detection and monitoring can benefit from a multiple-template strategy that analyzes DNA from circulating tumor cells (ctcDNA) and circulating cell free DNA (ccfDNA) in blood, as well as from tissue biopsies, according to new NCI-supported clinical trial published by scientists from Cynvenio Biosystems, Inc., and collaborators. The new research was published online in the journal Oncotarget.

Genome Web: Mt. Sinai Studying CTCs, ctDNA in Context of Triple Negative Breast Cancer

April 1, 2016 - Genome web article highlighting a trial by researchers at Mount Sinai to evaluate the genomic profiles of ctDNA and CTCs as well as phenotypic features of CTCs in patients with triple negative breast cancer to study the relationships between the two and how they correlate with disease. The group will use Cynvenio's LiquidBiopsy microfluidic system to isolate CTCs, ctDNA, and germline DNA.

Cynvenio Announces Availability of Concordia, a New Cell-free DNA Purification Upgrade for its LiquidBiopsy Whole Blood Enrichment Platform

February 10, 2016 – Cynvenio announces the availability of the Concordia™ cell-free DNA (cfDNA) purification sample preparation upgrade for its multi-template analysis LiquidBiopsy® platform. When coupled with Thermo Fisher Scientific’s Ion Torrent™ next-generation sequencing (NGS) systems, Cynvenio’s workflow provides a comprehensive molecular characterization of tumor cell DNA for cancer research samples from a standard blood draw.

Cynvenio and ATGen Open Recruitment for New LiquidBiopsy Clinical Research Study in Triple Negative Breast Cancer

December 28, 2015 – Cynvenio Biosystems, Inc. and ATGen Global, a Korea-based biotech company, announced the launch of a pilot study to evaluate a new method for early detection of cancer in women who have completed treatment for triple-negative breast cancer (TNBC) and show no radiographic signs of metastases.

Cynvenio Biosystems Announces $25.5 million Series B Financing

June 16, 2015 – Cynvenio Biosystems, Inc. announces the completion a $25.5 million Series B equity financing. Proceeds from the investment will be used to advance the company’s clinical development and commercialization programs. The Series B round was led by Livzon Pharmaceutical Group, Inc. a diversified drug, diagnostics and healthcare company based in Zhuhai, P.R. China. Other investors included Greenwoods Private Equity Funds (Shanghai) and Syno Capital (New York), among others.

Thermo Fisher Scientific Press Release:
New Innovations and Research Collaborations in the Cloud Drive Era of Precision Medicine

April 20, 2015 –Thermo Fisher Scientific unveils new innovations for research aimed at addressing the growing need for early detection, better prognosis, and more effective cancer treatments in the future. These new products, including Cynvenio's LiquidBiopsy platform, are being featured at the American Association for Cancer Research (AACR) 2015 Annual Meeting, booth #1501 in Philadelphia, Pa.